$VINC
Vincerx Pharma, Inc.

2023 Q1 Form 10-K Financial Statement

#000119312523082258 Filed on March 28, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.512M $4.050M $18.95M
YoY Change -20.23% -24.57% -16.04%
% of Gross Profit
Research & Development $10.59M $11.37M $52.15M
YoY Change -33.71% -7.82% 30.12%
% of Gross Profit
Depreciation & Amortization $13.00K $14.00K $54.00K
YoY Change -7.14% -44.0% 116.0%
% of Gross Profit
Operating Expenses $15.10M $15.42M $73.57M
YoY Change -30.18% -12.9% 17.43%
Operating Profit -$15.10M -$73.57M
YoY Change -30.18% 17.43%
Interest Expense $484.0K $429.0K $6.967M
YoY Change -90.71% -96.19% -70.17%
% of Operating Profit
Other Income/Expense, Net $758.0K $1.351M $8.207M
YoY Change -9575.0% -6533.33% -102687.5%
Pretax Income -$14.34M -$13.64M -$65.37M
YoY Change -12.68% 110.8% 66.3%
Income Tax
% Of Pretax Income
Net Earnings -$14.34M -$13.64M -$65.37M
YoY Change -12.68% 110.8% 66.3%
Net Earnings / Revenue
Basic Earnings Per Share -$0.68 -$3.11
Diluted Earnings Per Share -$0.68 -$0.65 -$3.11
COMMON SHARES
Basic Shares Outstanding 21.25M 21.19M 21.03K
Diluted Shares Outstanding 21.19K 21.03K

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.77M $52.46M $52.46M
YoY Change -58.78% -52.93% -52.93%
Cash & Equivalents $4.489M $11.66M $11.66M
Short-Term Investments $35.28M $40.80M $40.80M
Other Short-Term Assets $3.362M $3.301M $2.133M
YoY Change 113.05% 3374.74% 458.38%
Inventory
Prepaid Expenses $807.0K $134.0K
Receivables
Other Receivables
Total Short-Term Assets $44.01M $55.96M $55.96M
YoY Change -55.12% -49.96% -49.96%
LONG-TERM ASSETS
Property, Plant & Equipment $164.0K $177.0K $3.241M
YoY Change -95.85% -24.03% -22.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $354.0K $81.00K $81.00K
YoY Change -81.04% -95.1% -95.1%
Total Long-Term Assets $3.441M $3.322M $3.322M
YoY Change -40.85% -43.07% -43.07%
TOTAL ASSETS
Total Short-Term Assets $44.01M $55.96M $55.96M
Total Long-Term Assets $3.441M $3.322M $3.322M
Total Assets $47.45M $59.29M $59.29M
YoY Change -54.32% -49.62% -49.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.173M $3.065M $3.065M
YoY Change 82.31% 51.81% 51.81%
Accrued Expenses $3.355M $4.923M $5.947M
YoY Change 293.78% 4.41% 705.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.71M $9.156M $9.156M
YoY Change -7.05% -34.22% -34.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $50.00K $50.00K $2.462M
YoY Change -98.43% -98.54% -28.35%
Total Long-Term Liabilities $50.00K $50.00K $2.462M
YoY Change -98.43% -98.54% -28.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.71M $9.156M $9.156M
Total Long-Term Liabilities $50.00K $50.00K $2.462M
Total Liabilities $12.98M $11.62M $11.62M
YoY Change -11.75% -33.06% -33.06%
SHAREHOLDERS EQUITY
Retained Earnings -$135.7M -$121.3M
YoY Change 116.79%
Common Stock $2.000K $2.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $34.47M $47.67M $47.67M
YoY Change
Total Liabilities & Shareholders Equity $47.45M $59.29M $59.29M
YoY Change -54.32% -49.62% -49.62%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$14.34M -$13.64M -$65.37M
YoY Change -12.68% 110.8% 66.3%
Depreciation, Depletion And Amortization $13.00K $14.00K $54.00K
YoY Change -7.14% -44.0% 116.0%
Cash From Operating Activities -$13.09M -$13.82M -$59.60M
YoY Change -12.88% 20.29% 78.44%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $5.885M -$20.38M -$40.58M
YoY Change 711.56%
Cash From Investing Activities $5.885M -$20.38M -$40.58M
YoY Change 254687.5% 671.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.000K 38.00K 280.0K
YoY Change -86.57% -99.68%
NET CHANGE
Cash From Operating Activities -13.09M -13.82M -59.60M
Cash From Investing Activities 5.885M -20.38M -40.58M
Cash From Financing Activities 3.000K 38.00K 280.0K
Net Change In Cash -7.174M -34.16M -99.83M
YoY Change -52.26% 204.72% -300.49%
FREE CASH FLOW
Cash From Operating Activities -$13.09M -$13.82M -$59.60M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$13.82M -$59.60M
YoY Change 20.38% 79.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001796129
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39244
CY2022 dei Entity Registrant Name
EntityRegistrantName
Vincerx Pharma, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-3197402
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
260 Sheridan Avenue, Suite 400
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94306
CY2022 dei City Area Code
CityAreaCode
650
CY2022 dei Local Phone Number
LocalPhoneNumber
800-6676
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2022 dei Trading Symbol
TradingSymbol
VINC
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
19800000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21245842
CY2021 us-gaap Fair Value Net Derivative Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List
FairValueNetDerivativeAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#MarketableSecuritiesUnrealizedGainLoss
CY2022 us-gaap Fair Value Net Derivative Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List
FairValueNetDerivativeAssetLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#MarketableSecuritiesUnrealizedGainLoss
CY2022 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2022 dei Auditor Location
AuditorLocation
Whippany, New Jersey
CY2022 dei Auditor Firm
AuditorFirmId
100
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11663000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111459000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
70000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
105000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
40796000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
134000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
182000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3301000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21057560
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
169030000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
156311000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
95000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
55964000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
111841000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3064000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3949000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
177000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
233000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
81000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1653000
CY2022Q4 us-gaap Assets
Assets
59286000
CY2021Q4 us-gaap Assets
Assets
117676000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3065000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2019000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4923000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4715000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1024000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
738000
CY2022Q4 vinc Common Stock Warrant Liabilities Current
CommonStockWarrantLiabilitiesCurrent
144000
CY2021Q4 vinc Common Stock Warrant Liabilities Current
CommonStockWarrantLiabilitiesCurrent
6447000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9156000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13919000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2412000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3436000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
50000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q4 us-gaap Liabilities
Liabilities
11618000
CY2021Q4 us-gaap Liabilities
Liabilities
17355000
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21242884
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21242884
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21057560
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-26000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121338000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55971000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47668000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
100321000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59286000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117676000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18953000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22575000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
52152000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
40081000
CY2022 us-gaap Restructuring Charges
RestructuringCharges
2469000
CY2021 us-gaap Restructuring Charges
RestructuringCharges
0
CY2022 us-gaap Operating Expenses
OperatingExpenses
73574000
CY2021 us-gaap Operating Expenses
OperatingExpenses
62656000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-73574000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-62656000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6303000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-23358000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
664000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
0
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1240000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8207000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
23350000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65367000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-39306000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
69000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-21000
CY2022 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-74000
CY2021 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65372000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39327000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.11
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.11
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.29
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.29
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21029
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21029
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17176
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17176
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
25379000
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3320000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47431000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40671000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
351000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2503000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23313000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-21000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-39306000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
100321000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
280000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12439000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
69000
CY2022 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-74000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65367000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47668000
CY2022 us-gaap Profit Loss
ProfitLoss
-65367000
CY2021 us-gaap Profit Loss
ProfitLoss
-39306000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
54000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25000
CY2022 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
12439000
CY2021 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
23313000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
885000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
315000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6303000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-23358000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
292000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3158000
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1041000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1572000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1571000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1046000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1528000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
208000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4715000
CY2022 vinc Increase Decreasein Lease Liabilities
IncreaseDecreaseinLeaseLiabilities
-738000
CY2021 vinc Increase Decreasein Lease Liabilities
IncreaseDecreaseinLeaseLiabilities
-90000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
50000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
CY2022 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0
CY2021 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-14000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59604000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33402000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
42978000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2400000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2022 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
CY2021 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5000000
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Nature of Business </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LSAC was initially formed on December 19, 2018 as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. In December 2020, the Merger Sub merged with and into Legacy Vincera Pharma, with Legacy Vincera Pharma surviving the Merger as a wholly- owned subsidiary of LSAC. In connection with the Business Combination, LSAC changed its name to Vincera Pharma, Inc., and subsequently in January 2021, changed its name to Vincerx Pharma, Inc. (together with its consolidated subsidiaries, the “Company”). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a clinical-stage biopharmaceutical company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The Company’s current pipeline is entirely derived from the Bayer License Agreement (see Note 4), pursuant to which the Company has been granted an exclusive, royalty-bearing, worldwide license under certain Bayer patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> to develop, use, manufacture, commercialize, sublicense, and distribute a clinical-stage and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> small molecule drug program and a preclinical stage bioconjugation platform, which includes next-generation antibody-drug conjugates and small molecule drug conjugates. The Company intends to use these product candidates to treat various cancers in a patient-specific, targeted approach. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s business operations, and those of third parties with whom the Company conducts business, have been, and could continue to be, adversely affected by health pandemics and epidemics, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> and by economic, business and political events, including inflation and the war in Ukraine. The extent to which these factors could continue to impact the Company’s business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence. Management continues to evaluate the impact of these factors on the Company’s current operations and future plans and intends to take appropriate measures to help alleviate their impact, but there can be no assurance that these efforts will be successful and that these factors will not continue to have a negative effect on the Company’s financial position and results of its operations. </div>
CY2022 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
0
CY2021 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
258000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40578000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5258000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
280000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
351000
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
47431000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
40671000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
280000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
88453000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-21000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-99831000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
49772000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111564000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61792000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11733000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111564000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0
CY2021 us-gaap Interest Paid Net
InterestPaidNet
25000
CY2022 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2503000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4264000
CY2022 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-12-19
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, common stock warrant liabilities and stock-based compensation. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </div></div></div>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Credit Risk </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical studies, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to transition from preclinical manufacturing to commercial production of products. </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company’s future product candidates will require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a material adverse impact on the Company. </div>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3295000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3295000
CY2021Q4 vinc Liability For Uncertainty In Income Taxes
LiabilityForUncertaintyInIncomeTaxes
0
CY2022Q4 vinc Liability For Uncertainty In Income Taxes
LiabilityForUncertaintyInIncomeTaxes
0
CY2021Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2022 us-gaap Government Assistance Amount
GovernmentAssistanceAmount
1000000
CY2022Q4 vinc Business Combination Share Issue Ratio
BusinessCombinationShareIssueRatio
0.570895
CY2022 vinc Date Of Licence Agreement
DateOfLicenceAgreement
2020-10-07
CY2021Q1 vinc Licence Fee Paid
LicenceFeePaid
5000000
CY2022Q4 vinc Licence Fee Payable
LicenceFeePayable
1000000
CY2022Q4 vinc Aggregate Milestone Payments Payable
AggregateMilestonePaymentsPayable
1000000000
CY2022Q2 vinc Percentage Of Employees Reduction
PercentageOfEmployeesReduction
0.33
CY2022Q4 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
2500000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
50590000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
40869000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
73000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
40796000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3301000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
95000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
256000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
258000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
79000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
177000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
233000
CY2022 us-gaap Depreciation
Depreciation
54000000
CY2021 us-gaap Depreciation
Depreciation
25000000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
297000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
531000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2042000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2514000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
923000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
759000
CY2022Q4 vinc Accrued Development Milestone
AccruedDevelopmentMilestone
1000000
CY2021Q4 vinc Accrued Development Milestone
AccruedDevelopmentMilestone
0
CY2022Q4 vinc Accrued Manufacturing Clinical Trial And Related Current
AccruedManufacturingClinicalTrialAndRelatedCurrent
661000
CY2021Q4 vinc Accrued Manufacturing Clinical Trial And Related Current
AccruedManufacturingClinicalTrialAndRelatedCurrent
911000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4923000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4715000
CY2020Q4 vinc Date Of Lease Agreement
DateOfLeaseAgreement
P5Y
CY2020Q4 vinc Date Of Lease Commencement
DateOfLeaseCommencement
2021-01-01
CY2020Q4 us-gaap Lease Cost
LeaseCost
1200000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3400000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3100000
CY2022Q3 vinc Lessee Operating Sub Lease Term Of Contract
LesseeOperatingSubLeaseTermOfContract
P18M
CY2022Q3 vinc Lessee Operating Sub Lease Rent Amount
LesseeOperatingSubLeaseRentAmount
50000000
CY2022 us-gaap Sublease Income
SubleaseIncome
300000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1196000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
619000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2022 us-gaap Lease Cost
LeaseCost
1196000
CY2021 us-gaap Lease Cost
LeaseCost
619000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1048000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
380000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4264000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2022Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
1261000
CY2022Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
1284000
CY2022Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
1336000
CY2022Q4 us-gaap Contractual Obligation
ContractualObligation
3881000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
445000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3436000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21242884
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21057560
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1048
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P10Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2367000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.62
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
7000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
19
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3408
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.74
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2509000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.3
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.82
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1562000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
15.89
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4353
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.87
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
125000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1973000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
16.71
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2022Q4 vinc Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodTotalIntrinsicValue
5000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5200000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
3.3
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
18.62
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.851
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.763
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.028
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12439000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23313000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65367000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-39306000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21029
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21029
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17176
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17176
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.11
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.11
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.29
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.29
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7648000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6703000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-61091000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-39394000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4276000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
88000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-65367000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39306000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.007
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.01
CY2022 vinc Effective Income Tax Rate Reconciliation Fair Value Adjustment Of Warrants Percent
EffectiveIncomeTaxRateReconciliationFairValueAdjustmentOfWarrantsPercent
0.02
CY2021 vinc Effective Income Tax Rate Reconciliation Fair Value Adjustment Of Warrants Percent
EffectiveIncomeTaxRateReconciliationFairValueAdjustmentOfWarrantsPercent
0.124
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.007
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.014
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.012
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.229
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.326
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9639000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4035000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
6620000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
5164000
CY2022Q4 vinc Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
4198000
CY2021Q4 vinc Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
4723000
CY2022Q4 vinc Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
7314000
CY2021Q4 vinc Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
0
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1635000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
891000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
471000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
575000
CY2022Q4 vinc Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
722000
CY2021Q4 vinc Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
877000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30599000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
16265000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
29955000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15436000
CY2022Q4 vinc Deferred Tax Assets Net Valuation Allowances
DeferredTaxAssetsNetValuationAllowances
644000
CY2021Q4 vinc Deferred Tax Assets Net Valuation Allowances
DeferredTaxAssetsNetValuationAllowances
829000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
644000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
829000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
644000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
829000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14500000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12400000
CY2022 vinc Tax Credit Carry Forward Expiration Year
TaxCreditCarryForwardExpirationYear
P2039D
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 vinc Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
0
CY2021 vinc Unrecognized Tax Benefits Increase Decrease Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromCurrentPeriodTaxPositions
518000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
518000
CY2022 vinc Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
-164000
CY2022 vinc Unrecognized Tax Benefits Increase Decrease Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromCurrentPeriodTaxPositions
625000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
979000

Files In Submission

Name View Source Status
0001193125-23-082258-index-headers.html Edgar Link pending
0001193125-23-082258-index.html Edgar Link pending
0001193125-23-082258.txt Edgar Link pending
0001193125-23-082258-xbrl.zip Edgar Link pending
d470783d10k.htm Edgar Link pending
d470783dex231.htm Edgar Link pending
d470783dex311.htm Edgar Link pending
d470783dex312.htm Edgar Link pending
d470783dex321.htm Edgar Link pending
d470783dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g470783g01b19.jpg Edgar Link pending
g470783g01t24.jpg Edgar Link pending
g470783g01u11.jpg Edgar Link pending
g470783g01u14.jpg Edgar Link pending
g470783g01u15.jpg Edgar Link pending
g470783g01u20.jpg Edgar Link pending
g470783g01u23.jpg Edgar Link pending
g470783g01x12.jpg Edgar Link pending
g470783g01z22.jpg Edgar Link pending
g470783g02b19.jpg Edgar Link pending
g470783g02t24.jpg Edgar Link pending
g470783g02u11.jpg Edgar Link pending
g470783g02u23.jpg Edgar Link pending
g470783g02x12.jpg Edgar Link pending
g470783g02z22.jpg Edgar Link pending
g470783g03b19.jpg Edgar Link pending
g470783g03u11.jpg Edgar Link pending
g470783g03u23.jpg Edgar Link pending
g470783g03x12.jpg Edgar Link pending
g470783g03z22.jpg Edgar Link pending
g470783g04b19.jpg Edgar Link pending
g470783g04m23.jpg Edgar Link pending
g470783g83j18.jpg Edgar Link pending
g470783g83p09.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
d470783d10k_htm.xml Edgar Link completed
g470783g83q16.jpg Edgar Link pending
g470783g83v15.jpg Edgar Link pending
g470783g83w21.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vinc-20221231.xsd Edgar Link pending
vinc-20221231_cal.xml Edgar Link unprocessable
vinc-20221231_def.xml Edgar Link unprocessable
vinc-20221231_lab.xml Edgar Link unprocessable
vinc-20221231_pre.xml Edgar Link unprocessable